NCT04713176

Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients

A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of DW1248 With Remdesivir in Severe COVID-19 Patients

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 240 (actual)
• Sponsor: Daewoong Pharmaceutical Co. LTD. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

Efficacy and Safety of DWJ1248 with Remdesivir in Severe COVID-19 Patients

Conditions

• Severe COVID-19

Interventions

Type	Name	Description
DRUG	DWJ1248 with Remdesivir	1 tablet of DWJ1248 TID(up to 14 days) PO, Remdesivir(up to 5 or 10 days) IV
DRUG	Placebo with Remdesivir	1 tablet of placebo TID(up to 14 days) PO, Remdesivir(up to 5 or 10 days) IV

Timeline

• Start date: 2021-02-02
• Primary completion: 2022-05-02
• Completion: 2022-12-09
• First posted: 2021-01-19
• Last updated: 2023-09-29

Locations

1 site across 1 country: South Korea